At Clover, our innovative technology drives research and development for a new generation of vaccines that have the potential to improve health and wellbeing for millions.
The Trimer-Tag technology platform can trimerize* any protein of interest and target a broad spectrum of naturally trimerization-dependent disease targets. By employing the Trimer-Tag technology platform, we are able to produce innovative, covalently-trimerized fusion proteins to effectively target previously difficult to target pathways. The following diagram highlights the Trimer-Tag technology platform and the naturally trimerization-dependent disease targets that could potentially be addressed by harnessing our technology:
Platform for development of protein-based vaccines based on naturally trimerization-dependent targets.
Only trimerization technology platform globally for producing recombinant covalently-trimerized fusion proteins utilizing a human-derived trimerization tag.
Platform validation demonstrated for vaccines in the global SPECTRA Phase 2/3 data for SCB-2019 (CpG 1018/Alum).
* A “trimer” refers to a molecule or an anion formed by combination or association of three molecules or ions of the same substance. Trimerization is a chemical reaction that uses three identical molecules to produce a single trimer. Proteins that are created through the joining of two or more genes that originally coded for separate proteins and consist of three identical simpler parts are referred to as “trimeric fusion proteins.” Trimerization tag refers to a protein tag from the C-propeptide domain of procollagen (Trimer-Tag), which is capable of self-assembly into a disulfide bond-linked trimer.